Susan Rubin, MD
Neurology · Glenview, ILNPI 1972662518
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,616 of the $8,647 with a category attached, or 64.9%. 18 manufacturers reported payments, led by Novartis at 44.8% of the total. Reporting peaked in 2019 at $4,892 and has fallen 84.4% since, to $764 in 2025.
Across 80 payments — averaging $108.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Biogen$1K
- TG Therapeutics, Inc.$601
- EMD Serono, Inc.$546
- Banner Life Sciences, LLC$327
- AbbVie$287
- plus $2K from 12 others
Across 7 payments — averaging $28,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$185K
- Biogen$17K
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$2,66031%
- Travel & lodging$150%
- Food & beverage$5,61665%
- Education$2062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $3,876 |
| Biogen | 19 | $1,388 |
| TG Therapeutics, Inc. | 6 | $601 |
| EMD Serono, Inc. | 8 | $546 |
| Banner Life Sciences, LLC | 1 | $327 |
| AbbVie(2 entities) | 4 | $287 |
| Lundbeck LLC | 6 | $244 |
| Genentech USA, Inc. | 3 | $241 |
| Teva Pharmaceuticals USA, Inc. | 4 | $207 |
| Sanofi | 2 | $174 |
| AstraZeneca | 1 | $135 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| SK Life Science, Inc. | 1 | $97 |
| Amgen | 1 | $93 |
| Lilly USA, LLC | 2 | $89 |
| Inspire Medical Systems, Inc. | 2 | $86 |
| Biohaven Pharmaceuticals, Inc. | 1 | $84 |
| Genentech, Inc. | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,647 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 38 | $230,496 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 20 | $163,586 |
| BetaseronInterferon Beta-1b | 13 | $121,335 |
| Teriflunomide | 67 | $97,952 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $88,575 |
| Aimovig AutoinjectorErenumab-Aooe | 110 | $81,589 |
| Emgality PenGalcanezumab-Gnlm | 56 | $44,289 |
| GlatopaGlatiramer Acetate | 16 | $31,483 |
| Nurtec OdtRimegepant Sulfate | 17 | $24,742 |
| Glatiramer Acetate | 14 | $18,541 |
| UbrelvyUbrogepant | 15 | $16,476 |
| Emgality SyringeGalcanezumab-Gnlm | 23 | $15,608 |
| Dalfampridine ErDalfampridine | 58 | $15,344 |
| Dimethyl Fumarate | 26 | $8,167 |
| Gabapentin | 238 | $6,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $207 | $230,49638 claims |
| BiogenAvonex (4 Pack) | $1,388 | $88,57511 claims |
| AbbVieUbrelvy | $287 | $16,47615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.
Other neurology in Glenview
- Trupti GokaniGlenview$126K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.